AZNAstraZenecaRunning, no new patients
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 37 (planned)
- Started
- May 8, 2023
- Main results expected
- Feb 22, 2027
- Fully finished
- Feb 22, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of patients with Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
Measured over: Until 90 days after the last dose of study treatment
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05629234 · record last updated 2026-07-09 · checked 2026-11-09 15:47 UTC